Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Índice de masa corporal (IMC) y calidad de vida (CdV) en pacientes con cáncer (BMI-QoL)

19 de septiembre de 2026 actualizado por: Vincenzo Formica, University of Rome Tor Vergata

BMI is a simple and widely recorded variable that may capture obesity or cachexia in cancer patients. How BMI is associated to health-related quality of life (HR-QoL) in such patients is poorly investigated.

High BMI may be associated to obesity, an increased burden of comorbidity, reduced physical activity and, in some settings, to more aggressive oncological disease. On the other hand, low BMI may reflect enhanced weight loss, cachectic syndrome, higher tumor burden and adverse prognostic features which all deteriorate quality of life. The aim of the present study is to evaluate the association of BMI and HR-QoL as measured by the EORTC-QLQ-C30 or the EQ-5D-5L questionnaire in several cancer settings (such as localized vs metastatic or distinct primary tumors).

Descripción general del estudio

Estado

Reclutamiento

Descripción detallada

Health-related quality of life (HRQoL) might have a varied association with body weight in patients with solid cancer[1].

On one hand, low body weight may reflect cancer-related anorexia and weight loss and cachectic syndrome, which are associated with impaired performance status, deteriorated general conditions, and advanced cancer[2]. In such patients, the probability of recording a low Body Mass Index (BMI) and, concomitantly, an inferior health-related quality of life (HRQoL, as a patient reported outcome, PRO) is high.

On the other hand, some of the hormonal mediators found at increased concentration in obese patients, such as insulin-like growth factor (IGF), have been demonstrated to be involved in biological pathways that favor improved HRQoL[3].

An additional apparent contradiction is that obesity and high BMI may represent in some cancer settings an adverse feature. In particular, obesity is associated with an increased risk of developing certain tumor types and, in some cancer patients with radically resected primary tumors, of cancer relapse[4]. Moreover high BMI is often associated with an increased burden of comorbidity (e.g. cardiovascular and metabolic diseases)[5] and reduced physical activity. All these factors may reduce HRQoL.

Studies investigating specific associations between BMI and HRQoL in specific cancer settings are therefore warranted.

The present prospective observational cohort study aims to investigate the relationship between BMI and PRO-HRQoL as measured by the EORTC-QLQ-C30 or the EQ-5D-5L questionnaire [6] in different primary tumors (breast, lung, colorectal and others) and in different cancer stages (localized vs metastatic). Patients will also be stratified according to the presence of cardiovascular and metabolic comorbidities, the Karnofsky Performance status, and the oncological treatment received (systemic treatment vs radically resected patients on follow-up). If available, retrospective data will be used to train possible predictive models.

STUDY PROCEDURES Study participation will be offered to all consecutive patients with a histologically confirmed diagnosis of solid tumor referred to the Medical Oncology Units of the S.I.C.O.G. cooperative group (http://www.sicog.it/). Upon acceptance, patients will sign an informed consent forms and be asked to fill out the EORTC QLQ C30 or EQ-5D-5L questionnaire.

All common anthropometric, demographic, clinical, and biochemical variables will be recorded at the time of first referral (within three months).

Re-assessable variables, including re-administration of the EORTC QLQ-C30/EQ-5D-5L questionnaire, will be recorded every 4-6 months thereafter. All data will be stored in a prospectively maintained database.

Among recorded data will be: age, sex, weight, height, occupation, marital status, primary tumor site, tumor stage, possible metastatic sites, past and current type of oncological treatment, concomitant medications, Karnofsky Performance Status, vital signs, and routine and clinically relevant blood tests.

Patients will be oncologically managed according to standard practice. If indicated, patients will also be asked to provide consent for peripheral blood sampling for immune response evaluation. Association between BMI and PROs will be assessed using regression analyses across the different clinical settings identified.

STATISTICAL CONSIDERATIONS The design of the study hypothesizes that in metastatic patients an improved HR-QoL is associated with high BMI (non-cachectic patients) An 'exact single-stage design' will be followed [7]. According to historical data (endometrial cancer), 50% of patients with BMI < 30 have a high global health status score (GHS) of the EORTC QLQ C30 (i.e. a GHS score ≥ 80%, which would correspond to a EQ-5D-5L index ≥ 0.85) [8].

The hypothesis to be tested will be H0, P < P0 vs H1, P > P1, where P is the percentage of patients with GHS ≥ 80%. A one-tail alpha error of 0.05 and false-negative (beta) rate of 0.2 will be considered. P0 will be set at 50% and P1 at 65%, looking for a 15% increase in the percentage of high GHS scores among patients with BMI >30. The H0 hypothesis will be rejected and H1 accepted with a statistical power of 80% if at least 42 patients out of 69 with BMI > 30 report a GHS score ≥ 80.

Since BMI > 30 is observed in about 10% of all metastatic patients, a total of 690 metastatic patients will be required. Since metastatic patients represent about half of all cancer patients referred to Medical Oncology Units, a final sample size of 1380 cancer patients (all stages) will be set as the target number. Secondary analyses will evaluate the extent to which clinical and biochemical characteristics documented during the observation period moderate the association between BMI and HRQoL. Additionally, these analyses will quantify the relative contributions of both BMI and HRQoL to anticancer treatment outcomes and overall survival.

Tipo de estudio

De observación

Inscripción (Estimado)

1380

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Vincenzo Formica, MD, PhD
  • Número de teléfono: +390620908190
  • Correo electrónico: v.formica1@gmail.com

Copia de seguridad de contactos de estudio

  • Nombre: Cristiano Serci
  • Número de teléfono: +390620903247
  • Correo electrónico: cserci81@gmail.com

Ubicaciones de estudio

      • Rome, Italia, 00133
        • Reclutamiento
        • Tor Vergata University Hospital
        • Contacto:
          • Cristiano Serci
          • Número de teléfono: +390620908190

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

All consecutive patients with a histologically confirmed diagnosis of solid tumor referred to any of the Medical Oncology Units of the S.I.C.O.G. cooperative group (http://www.sicog.it/).

Descripción

Inclusion Criteria:

  1. Histologically confirmed diagnosis of solid tumor
  2. Age >18 years
  3. Signed informed consent
  4. Life expectancy > 12 weeks

Exclusion Criteria:

  1. Inability to fill out the questionnaires.
  2. Absence of a certain diagnosis of solid tumor (e.g. subjects on screening programs)
  3. Diagnosis of second malignancies that might bias results interpretation

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
patients with solid tumor

All consecutive patients with a histologically confirmed diagnosis of solid tumor referred to any of the Medical Oncology Units of the S.I.C.O.G. cooperative group (http://www.sicog.it/).

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
relationship between BMI and health-related quality-of-life scores according to tumor stage
Periodo de tiempo: Recruitment period of 36 months + follow-up period of 24 months since enrollment of last patient

To assess the relationship between BMI and health-related quality-of-life scores in localized vs metastatic cancer patients

Recruitment period of 36 months + follow-up period of 24 months since enrollment of last patient

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
relationship between BMI and health-related quality-of-life scores according to different clinical settings other than stage
Periodo de tiempo: Recruitment period of 36 months + follow-up period of 24 months since enrollment of last patient

- To assess the relationship between BMI and health-related quality-of-life scores according to:

  • primary tumor
  • presence vs absence of cardiovascular and/or metabolic comorbidities
  • Performance status
  • Ongoing chemotherapy treatment vs observation in disease-free patients (follow-up)
  • Other clinical and biochemical variables routinely assessed as common practice
Recruitment period of 36 months + follow-up period of 24 months since enrollment of last patient

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Colaboradores

Investigadores

  • Silla de estudio: Mario Roselli, Tor Vergata University Hospital

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

15 de enero de 2019

Finalización primaria (Estimado)

15 de enero de 2029

Finalización del estudio (Estimado)

15 de enero de 2034

Fechas de registro del estudio

Enviado por primera vez

11 de marzo de 2019

Primero enviado que cumplió con los criterios de control de calidad

11 de marzo de 2019

Publicado por primera vez (Actual)

13 de marzo de 2019

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

23 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

19 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir